Piper Jaffray analyst, Christopher Raymond, reiterated an Overweight rating and $450.00 price target on Regeneron Pharma (NASDAQ: REGN) following a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE